Physician profile
Moran Gotesman
NPI 1225326903
$5,927.80
in general payments reported to CMS, 2019-2025
20 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $1,063 · 2021: $228 · 2022: $1,321 · 2023: $162 · 2024: $2,020 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,320 · Food and Beverage: $1,062 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,320.00 |
| Food and Beverage | $1,062.26 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $1,455.18 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,297.70 | 2019-2023 | |
| Emmaus Medical, INC. | $1,049.39 | 2020-2025 | Endari |
| Novo Nordisk INC | $685.43 | 2019-2025 | Novoseven, Novoeight, Rebinyn |
| Novartis Pharmaceuticals Corporation | $358.04 | 2019-2022 | |
| Amgen INC. | $250.80 | 2019-2021 | |
| Pfizer INC. | $209.96 | 2019-2025 | |
| Genentech USA, INC. | $150.92 | 2019-2025 | Hemlibra |
| Genzyme Corporation | $136.37 | 2023-2025 | |
| Genentech, INC. | $120.91 | 2019 | |
| Grifols USA, LLC | $45.14 | 2019-2023 | Thrombate III |
| Tesaro, INC. | $27.01 | 2019 | |
| Global Blood Therapeutics, INC. | $23.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.49 | 2019 | |
| Seagen INC. | $22.83 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.37 | 2019 | |
| Eisai INC. | $20.86 | 2020 | |
| Rare Disease Therapeutics, INC. | $15.33 | 2025 | Xromi |
| Alexion Pharmaceuticals, INC. | $13.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moran Gotesman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.